üîπ FRAME A ‚Äî Pregnancy physiology ‚Üí GDM (normal ‚Üí pathology)

How do placental hormones induce insulin resistance during normal pregnancy?

Why does insulin resistance increase progressively from mid-pregnancy to the third trimester?

How do pancreatic beta cells normally compensate for pregnancy-induced insulin resistance?

What failure in beta-cell adaptation leads to the development of GDM?

Why does GDM typically manifest between 24‚Äì28 weeks of gestation?

How does maternal adiposity amplify pregnancy-related insulin resistance?

Why does insulin resistance rapidly abate after delivery?

How does normal pregnancy physiology resemble a temporary type 2 diabetes‚Äìlike state?

What differentiates normal pregnancy insulin resistance from pathological GDM?

Why is GDM considered a failure of compensation rather than a primary insulin resistance disorder?

üîπ FRAME B ‚Äî Maternal hyperglycemia ‚Üí fetal macrosomia (Pedersen / HAPO)

Using the modified Pedersen hypothesis, explain how maternal hyperglycemia leads to fetal macrosomia.

Why does maternal glucose, but not insulin, cross the placenta?

How does fetal hyperinsulinemia act as an anabolic hormone?

Why is fetal fat deposition disproportionately increased in the abdomen and shoulders?

How does placental GLUT upregulation contribute to fetal overgrowth?

What role does placental mTOR activation play in fetal nutrient supply?

Why are post-prandial glucose levels stronger predictors of macrosomia than fasting levels?

How does intermittent maternal hyperglycemia affect fetal insulin secretion differently from sustained hyperglycemia?

Why does fetal hyperinsulinemia persist immediately after birth?

How does this mechanism explain neonatal hypoglycemia?

üîπ FRAME C ‚Äî Epidemiology & risk amplification

Why does GDM prevalence vary widely between populations?

How does background type 2 diabetes prevalence influence GDM rates?

Why is ethnicity an independent risk factor for GDM?

How does obesity increase GDM risk beyond simple insulin resistance?

Why does maternal age correlate with rising GDM incidence?

How does prior macrosomia increase the risk of GDM in subsequent pregnancies?

Why is polycystic ovary syndrome associated with higher GDM risk?

How do genetic susceptibility and environment interact in GDM risk?

Why do low- and middle-income countries show rising GDM prevalence?

How do screening criteria differences inflate or deflate reported prevalence?

üîπ FRAME D ‚Äî Postpartum progression (GDM ‚Üí T2DM)

Why does GDM dramatically increase the risk of future type 2 diabetes?

How does declining beta-cell compensation persist after pregnancy?

Why is postpartum glucose tolerance often abnormal despite pregnancy resolution?

What proportion of women with GDM develop T2DM within 5‚Äì10 years?

Why is GDM considered a marker of latent metabolic syndrome?

How does weight gain accelerate beta-cell deterioration after GDM?

Why does insulin resistance remain elevated postpartum in some women?

How do inflammatory markers predict post-GDM diabetes progression?

Why is GDM recurrence common in subsequent pregnancies?

How does breastfeeding reduce maternal T2DM risk?

üîπ FRAME E ‚Äî Guidelines & diagnostic variability

Why do ADA, NICE, WHO, and IADPSG use different GDM diagnostic thresholds?

How do one-step and two-step screening approaches alter GDM prevalence?

Why is universal screening recommended at 24‚Äì28 weeks?

Why should high-risk women be screened earlier than 15 weeks?

How do HbA1c limitations affect its role in GDM diagnosis?

Why do fasting and post-load thresholds differ across guidelines?

How do guideline differences impact health system burden?

Why is standardization of GDM diagnosis still unresolved?

How do diagnostic criteria influence downstream treatment rates?

Why is early detection universally emphasized despite threshold disagreement?

üîπ FRAME F ‚Äî Intervention & monitoring (proper scope)

Why is lifestyle modification first-line therapy in GDM?

When does diet and exercise become insufficient for glycemic control?

Why is insulin considered the safest pharmacologic option in pregnancy?

Why do metformin and glyburide raise safety concerns?

How does CGM improve glycemic control compared to SMBG?

Why is CGM adoption limited despite demonstrated benefits?

How do cost and access create inequities in GDM management?

Why does tight glycemic control increase hypoglycemia risk?

How does multidisciplinary care improve pregnancy outcomes?

Why is fetal growth monitoring essential in poorly controlled GDM?

üîπ FRAME G ‚Äî Reframing: transient vs chronic metabolic disease

Why does GDM usually resolve after delivery?

What evidence suggests GDM is not merely a transient pregnancy complication?

How does declining beta-cell function support a chronic risk model?

Why is GDM considered a prediabetes-like condition?

How does postpartum OGTT reflect concern for long-term metabolic risk?

Why does resolution of hyperglycemia not imply metabolic normalization?

How do obesity and insulin resistance persist beyond pregnancy?

Why is long-term surveillance recommended after GDM?

Should GDM be classified as a chronic metabolic risk state rather than a disease?

How does this reframing change postpartum care priorities?

üîπ FRAME H ‚Äî Intergenerational & developmental programming

How does in-utero hyperglycemia program long-term metabolic disease in offspring?

Why are children of GDM mothers at higher risk of obesity?

How does fetal hyperinsulinemia alter long-term insulin sensitivity?

Why does the HAPO study support a dose-response relationship?

How does maternal glucose affect offspring cardiovascular risk?

Why do metabolic consequences of GDM exposure appear in adolescence?

How does placental nutrient transport influence lifelong disease risk?

Why is the intrauterine environment critical for metabolic programming?

How does GDM contribute to the transgenerational diabetes cycle?

Why is offspring follow-up rarely implemented despite known risks?

üîπ FRAME I ‚Äî Systemic gaps & care-pathway failures

Why is postpartum follow-up after GDM consistently poor?

How does healthcare system fragmentation contribute to missed OGTT testing?

Why is GDM often treated as ‚Äúresolved‚Äù once pregnancy ends?

How do insurance and access barriers worsen long-term outcomes?

Why does responsibility for follow-up fall between obstetrics and primary care?

How does inadequate postpartum care increase T2DM incidence?

Why do guidelines fail to translate into real-world follow-up?

How does health inequity amplify post-GDM risk?

Why is patient noncompliance an incomplete explanation for missed follow-up?

How does reframing GDM as chronic risk expose systemic care failures?
